1. Home
  2. FFIN vs GKOS Comparison

FFIN vs GKOS Comparison

Compare FFIN & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FFIN
  • GKOS
  • Stock Information
  • Founded
  • FFIN 1890
  • GKOS 1998
  • Country
  • FFIN United States
  • GKOS United States
  • Employees
  • FFIN N/A
  • GKOS N/A
  • Industry
  • FFIN Major Banks
  • GKOS Medical/Dental Instruments
  • Sector
  • FFIN Finance
  • GKOS Health Care
  • Exchange
  • FFIN Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • FFIN 5.2B
  • GKOS 5.5B
  • IPO Year
  • FFIN N/A
  • GKOS 2015
  • Fundamental
  • Price
  • FFIN $34.92
  • GKOS $100.14
  • Analyst Decision
  • FFIN Hold
  • GKOS Strong Buy
  • Analyst Count
  • FFIN 4
  • GKOS 13
  • Target Price
  • FFIN $39.00
  • GKOS $135.15
  • AVG Volume (30 Days)
  • FFIN 517.8K
  • GKOS 909.8K
  • Earning Date
  • FFIN 07-17-2025
  • GKOS 07-30-2025
  • Dividend Yield
  • FFIN 2.18%
  • GKOS N/A
  • EPS Growth
  • FFIN 16.55
  • GKOS N/A
  • EPS
  • FFIN 1.62
  • GKOS N/A
  • Revenue
  • FFIN $553,583,000.00
  • GKOS $404,523,000.00
  • Revenue This Year
  • FFIN $19.60
  • GKOS $27.88
  • Revenue Next Year
  • FFIN $5.84
  • GKOS $27.60
  • P/E Ratio
  • FFIN $21.67
  • GKOS N/A
  • Revenue Growth
  • FFIN 13.33
  • GKOS 23.92
  • 52 Week Low
  • FFIN $27.85
  • GKOS $77.10
  • 52 Week High
  • FFIN $44.66
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • FFIN 44.70
  • GKOS 58.49
  • Support Level
  • FFIN $35.46
  • GKOS $97.54
  • Resistance Level
  • FFIN $37.65
  • GKOS $102.82
  • Average True Range (ATR)
  • FFIN 0.78
  • GKOS 3.51
  • MACD
  • FFIN -0.19
  • GKOS 0.67
  • Stochastic Oscillator
  • FFIN 9.60
  • GKOS 77.52

About FFIN First Financial Bankshares Inc.

First Financial Bankshares Inc is a financial and bank holding company. The company operates one line of business (community banking) located in a single geographic area (Texas). The company conducts a full-service commercial banking business through its subsidiaries. The loan portfolio segments of the company include Commercial and Industrial, Municipal, Agricultural, Construction and Development, Farm, Non-Owner Occupied and Owner Occupied Commercial Real Estate, Residential, Consumer Auto and Consumer Non-Auto. It derives maximum revenue from Construction and Development Segment.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: